The History of Entamoebiasis

Dietmar Steverding1

1Bob Champion Research and Education Building, Norwich Medical School, University of East Anglia, Norwich Research Park, Rosalind Franklin Road, Norwich NR4 7UQ, U.K.

**Corresponding author:** Dietmar Steverding, Email: d.steverding@uea.ac.uk

# Abstract

This review article summarises the history of amoebic dysentery (entamoebiasis) caused by *Entamoeba histolytica*. Initially, *Entamoeba* species were thought to be the most primitive extant eukaryotes, but more recent research revealed that they emerged relatively late in evolutionary history. Paleoparasitological data suggest that *E. histolytica* has been a parasite of humans since ancient times and was probably spread throughout the world by man during early human migration. By the end of the 19th century, it was established that *E. histolytica* was the etiological agent of amoebic dysentery and liver abscess. The issue over pathogenic and non-pathogenic strains of *E. histolytica* was resolved in the 1980s by the discovery of the morphologically indistinguishable harmless sister species *Entamoeba dispar*. Being mainly a disease of tropical and subtropical low-income countries, entamoebiasis cases have increased among travellers and immigrants arriving from endemic regions in recent years.

**Keywords:** Entamoebiasis; Amoebiasis; Amoebic Dysentery; Amoebic Liver Abscess; *Entamoeba histolytica*; *Entamoeba dispar*

# Key Findings

* *Entamoeba histolytica* has been a parasite of humans since ancient times
* In the 19th century, *E. histolytica* was established as the etiological agent of amoebic dysentery and liver abscess
* The dichotomy of *E. histolytica*/*E. dispar* was resolved in the 1980s
* *E. histolytica* infections have recently increased among travellers and immigrants arriving from endemic regions

# Introduction

Diarrhoeal diseases have been and still are one of the leading causes of death (Hénock Blaise and Dovie, 2007). The causes of diarrhoeal diseases are manifold and include viral, bacterial, and parasitic pathogens. The protozoan *Entamoeba histolytica* is the etiological agent of amoebic dysentery (entamoebiasis) in humans. The amoeba is found worldwide, however, the majority of entamoebiasis cases occur in developing countries. Each year, about 50 million people contract the infection, and approximately 100.000 individuals die from the disease (Zulfiqar et al., 2023).

The disease is transmitted orally via ingesting mature *E. histolytica* cysts in faecally-contaminated water or food, or from hands. In the small intestine, the cysts encyst and release trophozoites, which move into the large intestine. There, the trophozoites replicate by binary fission and form new cysts. Both trophozoites and cysts are passed with the faeces, although trophozoites are typically excreted with loose stools while cysts are released with formed excrements. Due to the protective wall, cysts can survive and remain infectious for up to 12 days in moist and cool environments and up to 30 days in water (Sanie et al., 2012), whereas trophozoites die rapidly outside the body. In most cases, trophozoites occur in the intestinal lumen (non-invasive infection or luminal entamoebiasis), causing no apparent disease manifestation (asymptomatic infection). In about 10-20% of cases (Uribe-Querol and Rosales, 2020), the trophozoites invade the mucosal lining of the intestine (intestinal disease), inducing amoebic colitis with severe abdominal pain, diarrhoea (which may contain blood and mucus), and fever. In rare cases, *E. histolytica* can cross the intestinal barrier and spread via the blood to infect other organs (extraintestinal entamoebiasis), leading to abscesses. The most common extraintestinal manifestation is the amoebic liver abscess. In rare cases, an amoebic liver abscess can rupture into the abdomen or chest, causing the formation of abscesses in the lungs and heart. Extraintestinal manifestation is a severe complication reaching mortality rates exceeding 20% in cases of amoebic pericarditis and pulmonary entamoebiasis. However, if intestinal entamoebiasis is treated appropriately, the prognosis is good and the mortality rate is less than 1% (Zulfiqar et al., 2023).

# Evolution of *E. histolytica*

The genus *Entamoeba* was previously considered to be the most primitive extant eukaryotic group (Clark, 2000; Cui et al., 2019). Because of atypical subcellular structures (lack of mitochondria, rough endoplasmic reticulum, and Golgi apparatus) and an unusual glycolytic metabolism (pyrophosphate-dependent glycolytic pathway enzymes) and based on phylogenetic analysis of the elongation factor-1α, it was suggested that entamoebae had diverged from the line of eukaryotes with mitochondria prior the endosymbiotic event of a protomitochondian (Hasegawa et al., 1993; Clark, 2000). For these reasons, entamoebae were regarded as the earliest eukaryotic cells and thus living relics. However, more recent research revealed that entamoebae do not represent the ancestral form of eukaryotic cells. There is more and more evidence that entamoebae emerged relatively late in evolution and that the absence of typical eukaryotic organelles has arisen through secondary loss during lifestyle adaptation. Direct evidence for the secondary loss of mitochondria in entamoebae came from identifying genes encoding proteins of mitochondrial origin (Clark and Roger, 1995; Arisue et al., 2002; van der Giezen et al., 2005). The discovery of a previously undescribed organelle of mitochondrial origin termed mitosome, to which the nuclear-encoded mitochondrial genes are targeted, suggests that entamoebae retained a greatly reduced version of the mitochondrion (Mai et al., 1999; Tovar et al., 1999). The demonstration of a continuous endoplasmic reticulum is further evidence that entamoebae developed quite late in evolution (Teixeira and Huston, 2008). In addition, small-subunit ribosomal RNA (ssrRNA) phylogenetic analysis revealed that entamoebae emerged more recently than several lineages of typical eukaryotes with mitochondria (Sogin, 1991; Cavalier-Smith, 1993).

The genus *Entamoeba* is classically divided into three groups of species that form cysts with 1, 4, or 8 nuclei, and one group of species that do not produce cysts. Previous ssrRNA sequence analysis seemed to verify the validity of the grouping of the cyst-forming species (Clark and Diamond, 1997; Silberman et al., 1999). The clustering of non-encysting species with the group of species forming cysts with 4 nuclei was taken as an indication that this trait was acquired due to secondary loss (Clark and Diamond, 1997). However, more recent phylogenetic relationship analyses revealed that newly discovered mononucleate cyst-producing species (*E. bovis* and *E. suis*) group with the clades of quadrinucleate cyst-producing species (Fig. 1) (Clark et al., 2006; Stensvold et al., 2010). This indicates that these mononucleated cyst-producing species are descended from quadrinucleate cyst-producing species (Stensvold et al., 2010). Phylogenetic studies also suggest that *Entamoeba* sp. producing cysts with 8 nuclei form the basal group, whereas those species making four-nucleated cysts constitute the most derived group (Silberman et al., 1999), which includes the human pathogen *E. histolytica*.

*Entamoeba histolytica* groups with the clade including *E. nuttalli*, *E. dispar*, *E. bangladeshi*, and *E. ecuadoriensis* (Fig. 1). The closest relative of *E. histolytica* is *E.* *nuttalli*, a non-pathogenic amoeba prevalent in wild and captive macaques (Tachibana et al., 2007; Cui et al., 2019). The second phylogenetically closest species to *E. histolytica* is *E. dispar,* which is morphologically not differentiable from *E. histolytica* but non-pathogenic to humans. The morphological indistinguishability of the two species was the reason why previous prevalence data of entamoebiasis were greatly overestimated, with *E. dispa*r infections being 10 times more common than *E. histolytica* infections (Gonin and Trudel, 2003). Of the other two species of the *E. histolytica* clade, *E. bangladeshi* is also morphologically indistinguishable from *E. histolytica* but is considered non-pathogenic (Royer et al., 2012; Cui et al., 2019), while *E. ecuadoriensis* was isolated from sewage; therefore, it remains unclear whether it is a free-living or parasitic species (Clark et al., 2006).

The analysis of the genome of *E. histolytica* revealed some interesting insights into the evolution of this pathogen. Noteworthy is the elimination of metabolic enzymes by secondary loss, including the loss of the Krebs cycle and respiratory chain proteins (Loftus et al., 2005). Genomic data also confirm the absence of a mitochondrial genome, which supports the finding that *E. histolytica* lacks a classical mitochondrion and possesses only a mitochondrion-derived mitosome (Loftus et al., 2005). On the other hand, the amoeba has gained a considerable number of metabolic enzyme-encoding genes (at least 68) via horizontal gene transfer from bacteria (Weedall and Hall, 2011; Das and Ganguly, 2014). Among these bacterial genes are those coding for fermenting enzymes driving the anaerobic metabolism of *E. histolytica* (Clark et al., 2007). The acquisition of most of these bacterial genes seems to be ancient as several orthologous genes have also been found in the distant relative *E. invadens* (Roy et al., 2006). The horizontal transfer of bacterial genes and the instability and plasticity of the genome of entamoebae have been important for the adaptive evolution of *E. histolytica* (Weedall and Hall, 2011).

# Historical evidence of *E. histolytica*

There is global evidence for the presence of *E. histolytica* in historical times. By using ELISA techniques to determine *E. histolytica*-specific antigens, the amoeba was detected in specimens from coprolites, latrines, cesspits, and human remains.

## Prehistoric times

The earliest evidence of modern strains of *E. histolytica* comes from sediment samples of archaeological sites in Switzerland, Greece, and France, dating back to 5700-2500 BP (Goncalves et al., 2004; Le Bailly and Bouchet, 2006, 2015). Thus, identification of *E. histolytica* in prehistoric Western and Southern Europe may suggest that entamoebiasis could have originated in the Old World in the Neolithic period (Le Bailly et al., 2016). However, since modern strains of *E. histolytica* were also detected in specimens from human remains and cesspits in the Americas dating back to pre-Columbian times (Fouant et al., 1982; Goncalves et al., 2004; Le Bailly et al., 2014), entamoebiasis has probably developed much earlier in human evolution.

## Antiquity

There are several detailed accounts of diarrhoeal diseases by ancient Chinese, Hebrew, Greek, and other chroniclers, but given the unspecific symptoms of dysentery, these reports do not necessarily describe entamoebiasis (Imperato, 1981). Nevertheless, the occurrence of *E. histolytic* infections in antiquity was confirmed by ELISA in samples from latrines, cesspits, pits, and sediments collected from six archaeological sites in Europe (Belgium, France, and Italy) dating from the Roman period (Goncalves et al., 2004; Le Bailly and Bouchet, 2006, 2015). In another sample from an occupation layer from an archaeological site in Israel of the same period, amoebic cysts attributed to *E. histolytica* were described microscopically (Witenberg, 1961). As the finding was solely based on microscopy, it is rather speculative whether the observed structures were indeed *E. histolytica* cysts (Le Bailly et al., 2016).

## Middle ages

The presence of *E. histolytica* during Medieval times in Europe was confirmed by ELISA analysis of samples from latrines/cesspits, human remains, occupation layers, and a tomb of six archaeological sites in Belgium, France, Latvia, and Switzerland (Goncalves et al., 2004; Le Bailly and Bouchet, 2006, 2015; Yeh et al., 2014; Graff et al., 2020). The protozoan parasite was also detected in two locations in Israel in latrine/cesspit samples dating back to the Crusader and Mamluk periods (Mitchell et al., 2008; Yeh et al., 2015). These findings may indicate that *E. histolytica* was introduced into medieval Israel by travellers from Europe (Le Bailly et al., 2016).

In the New World, the presence of *E. histolytica* in pre-Columbian times was potentially detected at four locations. In Chile and Peru, entamoebae were microscopically observed on mummies (Fouant et al., 1982). Since these findings were not confirmed by immunological techniques, it cannot be assumed beyond doubt that the observed cysts are from *E. histolytica*. However, a more recent study on a pre-Columbian human skeleton from Guadeloupe in the Caribbean recovered the protozoan parasite and, thus, proved that *E. histolytica* was present in the Americas before European colonisation (Le Bailly et al., 2014). Also, samples from cesspits at an archaeological site in North America dating back to the 12th-13th century tested positive for the presence of *E. histolytica* antigens (Goncalves et al., 2004). These latter two results indicate that *E. histolytica* was most likely introduced into the New World during the prehistoric population of the continent, similar to the spreading of soil-transmitted helminths to the Americas (Steverding, 2020).

## Modern era

*Entamoeba histolytica* was detected in latrine/cesspit samples of two archaeological sites in Belgium and France, dating back to the 17th-18th century (Goncalves et al., 2004; Le Bailly and Bouchet, 2015). At the same period, the parasite was also identified on a human skeleton from a cemetery in Guadeloupe (Le Bailly et al., 2014). As for the 19th century, the amoeba was discovered in samples from the Meadowlark cemetery in the USA, from cesspits in Argentina, and on a human skeleton in Guadeloupe (Goncalves et al., 2004; Le Bailly and Bouchet, 2006; Le Bailly et al., 2014).

The 19th century was the era when *E. histolytica* was discovered and identified as the causative agent of amoebic dysentery and amoebic liver abscess. In the earlier part of the century, several British physicians gave accounts of dysentery associated with liver disease in India. In 1818, the Scottish physician and surgeon Sir George Ballingall (1780-1855) published a book on fever, dysentery, and liver complaints among European troops in India, in which he described “*…the existence of a liver affection in most of the cases of colonitis…*” (Ballingall, 1818). Similar observations were made by the Irish surgeon Sir James Annesley (1774-1847) during his time at the Madras General Hospital, which he published in a two-volume book in 1828. He described the disease as “*hepatic dysentery*” but was unsure about the root cause of the disease: the liver abscess or the dysentery (Annesley, 1828). Nevertheless, from the clinical symptoms Annesley recorded, it is clear that he was describing entamoebiasis. Four years later, the Scottish surgeon William Twining (1790-1835), while working as commander-in-chief of the Indian army in Bengal, confirmed Annesley’s observations (Twining 1832). In 1846, the English physician Edmund Alexander Parkes (1819-1876) published a book connecting liver abscesses with dysentery (Parkes, 1846).

In 1875, the Russian medical doctor Fedor Aleksandrevitch Lösch (alternatively spelt as Fyodor Alexandrovich Lesh) (1840-1903) published probably the first detailed description of a case of amoebic dysentery (Lösch, 1875). The reported case concerned a 24-year-old farmer who was admitted to the clinic of Prof. E. Eichwald in St. Petersburg on the 3rd of November 1873. Having had severe diarrhoea for months, the patient was in poor condition. Lösch’s meticulous documentation and thorough analyses of the case were crucial in clarifying the cause of amoebic dysentery. For instance, the regular examination of stools revealed that at times the patient was releasing amoebas on a massive scale. Lösch described the patient’s stools as thin, strong-smelling, and red-brown coloured, containing significant amounts of yellowish-white and greyish-coloured lumps of mucus and pus. After 4 months, the patient developed pleuritis accompanied by the disappearance of the amoebas in the stools. Lösch noticed that the vanishing of the amoebas had a positive effect on the enteritis and the consistency of the stools. However, on the 12th of April 1874, the patient eventually died suffering from symptoms of severe anaemia and general exhaustion. The post-mortem inspection revealed that the mucous membrane of the large intestine was thickened and swollen due to the inflammatory infiltration of the submucosal tissue. In his publication, Lösch also described the observed amoebas in great detail, including form and size with intracellular structures, and type of locomotion, and provided detailed drawings of the parasite (Fig. 2), which he named *Amoeba coli*. However, Lösch thought that the amoebas were not responsible for the patient’s dysentery but instead inhabited the patient’s intestine later during the disease, triggering the inflammation.

In the following years, several reports were published on the discovery of amoebas in patients with diarrhoeal diseases. During an expedition to investigate the cholera epidemics in Egypt and India of 1883, the German physician and microbiologist Robert Koch (1843-1910) described five cases of dysentery, two of which included liver abscesses (Koch and Gaffky, 1887). Koch noted numerous amoebas in colonic ulcers, and in tissues and capillaries near hepatic abscesses. Contrary to Lösch, Koch concluded that the amoebas might be responsible for the pathogenesis of the disease. Over the course of 2 years at the General Hospital in Alexandria, Koch’s former student, Stephan Kartulis (1852-1920), observed over 150 cases of diarrhoea patients with amoebas in their stool (Kartulis, 1886). In 1887, the Czech pathologist Jaroslav Hlava (1855-1924) reported that he had detected amoebas in 60 cases of dysentery while working in Prague (Hlava, 1887). The first description of amoebas in a case of dysentery and liver abscess in the New World was by the Canadian physician William Osler (1849-1919) at the Johns Hopkins Hospital in 1890 (Osler, 1890). Several more cases of US patients suffering from dysentery with amoebas in the stools were subsequently published (Imperato, 1981).

In 1891, the American pathologist William Thomas Councilman (1854-1933) and the Canadian physician and parasitologist [Henri Amadée Lafleur (1863-1939)](https://www.abebooks.co.uk/book-search/author/councilman-william-thomas-henri-amad%E9e/) published a monograph reviewing 15 cases of amoebic dysentery (Councilman and Lafleur, 1891). The two were the first to recognise that amoebic dysentery is a distinct clinical disease caused by a specific pathogen. They named the causative agent *Amoeba dysenteriae* and coined the terms "amoebic dysentery" and "amoebic abscess of the liver." Performing numerous animal experiments, the German bacteriologist Walter Kruse (1864-1943) and the Italian medical officer Alessandro Pasquale demonstrated in 1894 that amoebic dysentery was directly caused by the amoebas (Kruse and Pasquale, 1894). Priorly, it was thought that the amoebas were opportunistic protozoans that exacerbated existing lesions (Imperato, 1981). Already one year earlier, the German internist and surgeon Heinrich Irenaeus Quincke (1842-1922) and the German physician and microbiologist Ernst Roos (1866-1926) described the cyst form of the amoebas and showed that cysts caused dysentery when given orally (Quincke and Roos, 1893).

With the discovery of amoebas as causative agents of dysentery, there came confusion regarding the naming of the pathogen. Whereas the Americans called the dysentery-causing organism *A. dysenteriae*, the Europeans called it *Amoeba coli* (Lösch) or *A. coli felis* (Imperato, 1981). Quincke and Roos proposed the name *Amoeba intestini vulgaris* for a non-pathogenic amoeba found in humans (Quincke and Roos, 1893). In 1897, the Italian microbiologists Oddo Casagrandi (1872-1943) and Pietro Barbagallo (1868-?) also described a non-pathogenic amoeba species and named it *Entamoeba hominis* (Casagrandi and Barbagallo, 1897). Already in previous years, several researchers observed apparently harmless amoebas in patients without dysentery (Imperato, 1981). Both *A. intestini vulgaris* and *E. hominis* are probably identical to *Entamoeba coli*. Eventually, in 1903, it was the German zoologist Fritz Schaudinn (1871-1906; Fig. 3) who suggested the name *Entamoeba histolytica* for the pathogenic amoeba species because of its ability to destroy tissue and *E. coli* (Lösch) for the harmless amoeba species (Schaudinn, 1903).

Already in 1900, the American tropical medicine specialist Richard P. Strong (1872-1948) differentiated between pathogenic and harmless amoeba species. However, his work remained generally unnoticed (Imperato, 1981). The conclusive demonstration that *E. histolytica* is pathogenic and *E. coli* is non-pathogenic was eventually provided by the American physician Ernest Linwood Walker (1870-1952) and Andrew Watson Sellards (1884-1942) in 1913 (Walker and Sellards, 1913). By administering cysts of the two amoeba species to volunteers at a Manila prison, they were able to show that *E. histolytica* is the aetiological organism of amoebic dysentery in humans and that the encysted stage is the infectious agent. In addition, Walker and Sellards conceived the concept of “carrier”, infected individuals constantly passing *E. histolytica* in their stools, thus responsible for spreading the disease (Walker and Sellards, 1913). They also found that infections with *E. histolytica* do not always give rise to clinical disease, suggesting that this amoebic species could act as a commensal, a view rejected by others at that time (Elsdon-Dew, 1971).

By 1913, the life cycle of *E. histolytica* was finally unravelled by the Dutch parasitologists Willem Abraham Kuenen (1873-1951) and Nicholaas Hendrik Schwellengrebel (1885-1970) (Kuenen and Schwellengrebel, 1913). They reported that this amoeba species has three life-cycle stages: a quadrinucleate cyst, a commensal *minuta* form, and an invasive *magna* form. In 1919, the British protozoologist Clifford Dobell (1886-1949) published a monograph consolidating the current state of knowledge about the amoebas living in man and clarifying their systematics to put order into the conflicting taxonomy of the various amoebic species described thus far (Dobell, 1919). Hence, by the end of the 1910s, the main facts regarding the causative agents of amoebic dysentery, the transmission of the disease, and the life-cycle stages of the pathogen, including their food habits and where they live in the human body, were established.

## E. histolytica/E. dispar dichotomy

Early on, the low incidence of clinical disease in *E. histolytica* infections raised doubts about whether the amoebic species might generally be a harmless commensal of the human gut flora. It was the French parasitologist Émile Brumpt (1877-1951) who, in 1925, first suggested the existence of two morphologically identical but pathogenetically different species (Brumpt, 1925). Brumpt’s conclusion was based on experimental infections of human volunteers and kittens, a very sensitive animal model for determining the pathogenicity of *E. entamoeba*. He named the non-pathogenic species *Entamoeba dispar*. In 1931, the Yugoslavian physician and parasitologist Tshedomir (Čedomir) Simić (1896-1969) provided further evidence for the existence of two morphologically indistinguishable pathogenic and harmless species (Simić, 1931a,b,c). By serially passaging non-invasive amoebas between human volunteers and kittens and vice versa, Simić could show that neither humans nor kittens developed clinical symptoms of amoebic dysentery. However, as Brumpt and Simić could not distinguish the two species morphologically, their description of a non-pathogenic, from *E. histolytica* morphologically indistinguishable amoebic species did not get much support. On the contrary, in 1950, the British protozoologist and parasitologist Cecil Hoare (1892-1984) published a review article that cemented the view that the majority of cases of entamoebiasis are infections with non-pathogenic *E. histolytica* strains, while occasionally virulent strains of the amoeba lead to amoebic dysentery (Hoare, 1950).

The idea of two species gained momentum again in 1978 when it was reported that pathogenic and non-pathogenic *E. histolytica* isolates could be distinguished based on isozyme typing (Sargeaunt et al., 1978). In the following years, studies of clinical epidemiology (Gathiram and Jackson, 1985), genomic DNA (Tannich et al., 1989), antigenic differences (Petri et al., 1990), and ribosomal RNA (Clark and Diamond, 1991) confirmed that *E. histolytica* and *E. dispar* should be differentiated at the species level. Based on the accumulated evidence, Diamond and Clark redescribed *E. histolytica* in 1993 and separated it from *E. dispar* (Diamond and Clark, 1993). They emphasised that *E. dispar* and non-pathogenic *E. histolytica* are synonymous. In 1997, the World Health Organization endorsed the concept of two morphologically identical *Entamoeba* species with different pathogenicity, i.e., *E. histolytica* is the pathogenic species only causing invasive disease, while *E. dispar* is a non-pathogenic species causing no disease (WHO 1997).

## Drug development

Since the mid-19th century, ipecac, a drug produced from the dried root of the ipecacuanha plant (*[Carapichea ipecacuanha](https://en.wikipedia.org/wiki/Carapichea_ipecacuanha" \o "Carapichea ipecacuanha)*), has been widely used in India in the treatment of dysentery (Knight, 1980). In 1909, the American physicians Sidney Kohn Simon (1878-1936) and George Dock (1860-1951) independently advocated the use of salol-coated pills of ipecac in the treatment of amoebic dysentery (Simon, 1909; Dock, 1909). One year later, the British tropical medicine specialist Leonard Rogers (1868-1962) reported on the post-operation treatment of amoebic liver abscess with ipecac (Rogers, 1910). Inspired by the observation that emetine, the main constituent of ipecac, displays potent amoebicidal activity *in vitro* (Vedder. 1912), Rogers successfully treated both intestinal and hepatic amoebiasis with injectable salts of this isoquinoline alkaloid (Rogers, 1912). In 1916, the English pharmacologist and physiologist Henry Hallet Dale (1975-1968) tested the combination of emetine with bismuth, which had been previously reported by the Canadian physician William Edgar Deeks (1866-1931) to be an excellent remedy as bismuth-milk-saline for treating amoebic dysentery (Deeks, 1914), in entamoebiasis patients with promising results (Dale, 1916). The emetine-bismuth-iodide combination was widely accepted by British physicians for the treatment of amoebic dysentery for many years (Imperato, 1981).

In the following years, several other compounds were tested for their amoebicidal activity with different effectiveness, including arsenicals (acetarsol (acetarsone), carbasone, thiocarbazone, and glycobiarsol (bismuth glycolylarsanilate; milibis)), halogenated hydroxyquinolines (iodohydroxyquinoline, diiodohydroxyquinoline (diodoquin), and iodochlorhydroxyquin (clioquinol)), the [4-aminoquinoline](https://en.wikipedia.org/wiki/4-Aminoquinoline) chloroquine, and the 9-aminoacridine mepacrine (quinacrine; atabrine). Antibiotics were also investigated for their activity against *E. histolytica*, but most were non-specific or not very effective (Imperato, 1981). One of the antibiotics with amoebicidal activity was paromomycin (Fig. 4), an aminoglycoside antimicrobial produced by the bacterium *Streptomyces rimosus*, that was found in 1959 to be effective in treating entamoebiasis (Lopez Elias and Oliver-González, 1959). Paromomycin and diiodohydroxyquinoline (Fig. 4) are still used today for intraluminal carriage eradication (Chou and Austin, 2023). A third luminal anti-amoebic drug is diloxanide furoate (Fig. 4), which was developed in 1956 and has been in use since the 1960s (McAuley et al., 1992). Another antibiotic that is active against *E. histolytica* is the nitro-imidazole metronidazole (Fig. 4). Its effectiveness as an amoebicidal agent was demonstrated in 1966 in both intestinal and extraintestinal entamoebiasis (Powell et al., 1966). The derivatives tinidazole and ornidazole (Fig. 4) were shown in the 1970s to display similar amoebicidal activity as metronidazole (Arnold, 1978). The anti-amoebic activity of the related nitro-thiazole nitazoxanide (Fig. 4) was discovered in the 1990s (Gilles and Hoffman, 2002). All four nitro compounds are presently approved as first-line treatments for intestinal entamoebiasis and amoebic liver abscess (Chou and Austin, 2023).

## Current situation

Entamoebiasis remains a public health issue in many world regions, particularly in developing countries of the tropics and subtropics where poor hygiene and sanitation are a problem (Shirley et al., 2018). The highest prevalence rates of *E. histolytica* infections are in parts of Africa, Asia, and Latin America. In Africa, the highest prevalence rates of intestinal entamoebiasis were reported for the East African countries of Kenya (2012: 58.3%), Rwanda (2020: 54.5%), and Uganda (2012: 19.9%) (Nasrallah et al., 2022). In Asia, high proportions of people affected by entamoebiasis were found in the Gaza Strip (2005: 69.6%), the United Arab Emirates (2009-2011: 30%), in India (2011: 11.7%), and in 7 provinces of China (2001-2004: 11.1%) (Nasrallah et al., 2022). Latin American countries with high prevalence rates of *E. histolytica* infections in certain regions include Mexico (2006-2007: 42%) and Brazil (2004, 2008, and 2018: 14,3%, 13.9%, 13.4%) (Shirley et al., 2018; Nasrallah et al., 2022). However, the reported prevalence rates of entamoebiasis are probably overestimated in many cases because of the limitation to microscopically discriminate between the pathogenic species *E. histolytica* and the non-pathogenic species *E. dispar*.

In 2019, the burden of entamoebiasis was over 2.5 million DALYs (disability-adjusted life years), and the global age-standardised DALY rate of the disease (ASDALYR) was 36.77/100,000 (Fu et al., 2023). Whereas ASDALYRs of entamoebiasis in high, middle-high, and middle-income countries were quite low (0.80-10.34/100,000), the rate in low-middle and low-income countries was significantly higher (42.95-100.47), with Eastern sub-Saharan African countries having the highest ASDALYRs (114.64/100,000). The high ASDALYRs of Eastern sub-Saharan African countries are due to the high prevalence rates of entamoebiasis in these regions (see above). In terms of age groups, children under the age of 5 had the highest ASDALYRs (257.43/100,000) (Fu et al., 2023). Despite a declining global trend of ASDALYRs from 1990 to 2019, the high-income regions of North America and Australasia showed an increasing trend in the same period (Fu et al., 2023).

Although the prevalence of entamoebiasis in developed countries is generally low, the disease has increased among returning travellers and immigrants in recent years (Shirley et al., 2018). In addition, amoebic dysentery is one of the leading causes of infectious diarrhoea among holidaymakers coming back from *E. histolytica* endemic regions. The GeoSentinel Surveillance Network found that 12.5% of infectious gastrointestinal diseases diagnosed in returning travellers were due to entamoebiasis, with a rate of 14 per 1000 returned travellers (Swaminathan et al., 2009). People travelling to South America, the Middle East, and South Asia have the highest risks of acquiring an infection with *E. histolytica* (Swaminathan et al., 2009).

Another group of individuals residing in developed countries that have an increased risk of contracting entamoebiasis are men who have sex with men (Shirley et al., 2018). Sequence analysis suggested that in these cases, *E. histolytica* is transmitted from person to person (Hung et al., 2008). Additionally, it has been reported that HIV-positive men who have sex with men have a higher risk of invasive amoebic disease (Hung et al., 2008; Watanabe et al., 2011).

## Conclusion

Contrary to the previous belief that *E. histolytica* is a primitive eukaryotic organism lacking classical eukaryotic organelles, this pathogen has in fact evolved more recently. Furthermore, paleoparasitological research indicates that *E. histolytica* has been a parasite of humans for a long time. This can be deduced from the detection of *E. histolytica* at a few pre-Columbian archaeological sites, which suggests that the parasite was most likely introduced into the New World by the Palaeolithic hunter-gatherers peopling the American continent about 15,000 years ago. Thus, it can be hypothesised that *E. histolytica* may have been a parasite of humans for more than 15,000 years, suggesting that the amoeba may even be an heirloom parasite. However, to determine this with certainty, further evidence of the presence of *E. histolytica* in additional samples from various ancient pre-Columbian sites is needed.

Although *E. histolytica* was established as the causative agent of amoebic dysentery and liver abscess by the end of the 19th century, it remained a puzzle for a long time why some patients developed clinical symptoms while others did not. The initial idea that there are pathogenic and non-pathogenic strains of *E. histolytica* was not an implausible suggestion. Meanwhile, it is known that harmless gut commensals can have pathogenic strains. A prominent example would be the bacterium *Escherichia coli*. By the 1980s it was finally established that there are two morphologically indistinguishable amoeba species to be found in the human intestine: the pathogenic *E. histolytica* and the harmless *E. dispar*. As unusual as the existence of two morphologically indistinguishable *Entamoeba* species may seem, there are other examples of pathogenic species that cannot be morphologically differentiated but cause diverse disease symptoms, such as human pathogenic *Leishmania* species. Noteworthy is the fact that based on rRNA sequences, the genetic distance between *E. histolytica* and *E. dispar* is similar to that between humans and mice (Clark and Diamond, 1991).

Although entamoebiasis occurs worldwide, the majority of the disease is recorded in low-income countries in regions with poor sanitation, leading to contaminated water supply. More recently, however, imported entamoebiasis cases have increasingly been identified in non-endemic countries.

**Data availability.** The original contributions presented in the study are included in the article.

**Acknowledgements.** I would like to thank Springer Nature for confirming that I do not need permission to reuse Fig. 2 of Taf. X published by Lösch (1875).

**Author’s contribution.** DS conducted the literature search and wrote the manuscript.

# Financial support. This work received no external funding.

**Competing interests.** The author declares there are no conflicts of interest.

**Ethical standards.** Not applicable.

# References

**Annesley J** (1828) *Researches into the Causes, Nature, and Treatment of the More Prevalent Diseases of India, and of Warm Climates Generally*. London: Longman, Rees, Orme, Brown, and Green.

**Arisue N, Sánchez LB, Weiss LM, Müller M and Hashimoto, T** (2002) Mitochondrial‐type hsp70 genes of the amitochondriate protists, *Giardia intestinalis*, *Entamoeba histolytica* and two microsporidians. *Parasitology International*, **51**, 9-16. doi:10.1016/s1383-5769(01)00093-9

**Arnold K** (1978) Trends in the development of chemotherapy for parasitic diseases. *Southeast Asian Journal of Tropical Medicine and Public Health* **9**, 177-185.

**Ballingall G** (1818) *Practical Observations on Fever, Dysentery, and Liver Complaint, as They Occur amongst the European Troops in India, with Introductory Remarks on the Disadvantages of Selecting Boys for Indian Military Service.* Edinburgh: D. Brown and A. Constable.

**Brumpt É** (1925) Étude sommaire de l' *"Entamoeba dispar"* n. sp. Amibe à kystes quadrinucléés, parasite de l'homme. *Bulletin de l'Académie de Médecine (Paris)* **94**, 943-952.

**Casagrandi O and Barbagallo P** (1897) *Entamoeba hominis* s. *Amoeba coli* (Lösch). Studio biologico e clinico. [*Annali d'igiene sperimentale*](https://species.wikimedia.org/wiki/ISSN_0365-3161) **7**, 103-166.

**Cavalier-Smith T** (1993) Kingdom protozoa and its 19 phyla. *Microbiology Review*, **57**, 953-994. doi:[10.1128/mr.57.4.953-994.1993](https://doi.org/10.1128/mr.57.4.953-994.1993)

**Chou A and Austin RL** (2023) *Entamoeba histolytica* Infection. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.

**Clark CG** (2000) The evolution of *Entamoeba*, a cautionary tale. *Research in Microbiology* **151**, 599-603. doi:10.1016/s0923-2508(00)90127-x

**Clark CG and Diamond LS** (1991) Ribosomal RNA genes of 'pathogenic' and 'nonpathogenic' *Entamoeba histolytica* are distinct. *Molecular and Biochemical Parasitology* **49**, 297-302. doi:10.1016/0166-6851(91)90073-f

**Clark CG and Diamond LS** (1997) Intraspecific variation and phylogenetic relationships in the genus *Entamoeba* as revealed by riboprinting. *Journal of Eukaryotic Microbiology* **44**, 142-154. doi:10.1111/j.1550-7408.1997.tb05951.x

**Clark CG and Roger AJ** (1995) Direct evidence of secondary loss of mitochondria in *Entamoeba histolytica*. *Proceedings of the National Academy of Sciences of the United States of America* **92**, 6518-6521. doi:10.1073/pnas.92.14.6518

**Clark CG, Kaffashian F, Tawari B, Windsor JJ, Twigg-Flesner A, Davies-Morel MCG, Blessmann J, Ebert F, Peschel B, Van AL, Jackson CJ, Macfarlane L and Tannich E** (2006) New insights into the phylogeny of *Entamoeba* species provided by analysis of four new small-subunit rRNA genes. *International Journal of Systematic and Evolutionary Microbiology* **56**, 2235-2239. doi:10.1099/ijs.0.64208-0

**Clark CG, Alsmark UCM, Tazreiter M, Saito-Nakano Y, Ali V, Marion S, Weber C, Mukherjee C, Bruchhaus I, Tannich E, Leippe M, Sicheritz-Ponten T, Foster PG, Samuelson J, Noël CJ, Hirt RP, Embley TM, Gilchrist CA, Mann BJ, Singh U, Ackers JP, Bhattacharya S, Bhattacharya A, Lohia A, Guillén N, Duchêne M, Nozaki T and Hall N** (2007) Structure and content of the *Entamoeba histolytica* genome. *Advances in Parasitology* **65**, 51-190. doi:10.1016/S0065-308X(07)65002-7

**Councilman WT and Lafleur HA** (1891) Amoebic dysentery. *Johns Hopkins Hospital Report* **2**, 395-548.

**Cui Z, Li J, Chen Y and Zhang L** (2019) Molecular epidemiology, evolution, and phylogeny of *Entamoeba* spp. *Infection, Genetics and Evolution* **75**, 104018. doi:10.1016/j.meegid.2019.104018

**Dale HH** (1916) Treatment of carriers of amoebic dysentery. Note on the use of the double iodide of emetine and bismuth. *Lancet* **188**, 183-184.

**Das K and Ganguly S** (2014) Evolutionary genomics and population structure of *Entamoeba histolytica*. *Computational and Structural Biotechnology Journal* **12**, 26-33. doi:10.1016/j.csbj.2014.10.001

**Deeks WE** (1914) Dysenteries in the Canal Zone, with special reference to amoebic dysentery. *Annals of Tropical Medicine and Parasitology* **8**, 321-352. doi:10.1080/00034983.1914.11687649

**Diamond LS and Clark CG** (1993) A redescription of *Entamoeba histolytica* Schaudinn, 1903 (emended Walker, 1911) separating it from *Entamoeba dispar* Brumpt, 1925. *Journal of Eukaryotic Microbiology* **40,** 340-344. doi:10.1111/j.1550-7408.1993.tb04926.x

**Dobell C** (1919) *The Amoeba Living in Man: A Zoological Monograph.* London: John Bale, Sons & Danielsson. doi:[10.5962/bhl.title.10172](https://doi.org/10.5962/bhl.title.10172)

**Dock G** (1909) A note on the ipecac treatment of amoebic dysentery. *New York Medical Journal* **90**, 49-50.

**Elson-Dew R** (1971) Amebiasis as a world problem. *Bulletin of the New York Academy of Medicine* **47**, 438-447.

**Fouant MM, Allison, M, Gerszten E and Focacci A G** (1982) Parásitos intestinales entre los indígenas precolombinos. *Chungara Revista de Antropología Chilena* **9**, 285-299.

**Fu X, Zhong Y, Chen L, Ge M, Yu M, Sun Y and Shen L** (2023) Global burden and trends of the *Entamoeba* infection-associated diseases from 1990 to 2019: An observational trend study. *Acta Tropica* **240**, 106866. doi:10.1016/j.actatropica.2023.106866

[**Gathiram**](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(85)91263-2/fulltext) **V and** [**Jackson**](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(85)91263-2/fulltext) **TFHG** (1985) Frequency distribution of *Entamoeba histolytica* zymodemes in a rural South African population. *Lancet* **325**, 719-721. doi:10.1016/s0140-6736(85)91263-2

**Gilles HM and Hoffman PS** (2002) Treatment of intestinal parasitic infections: a review of nitazoxanide. *Trends in Parasitology* **18,** 95-97. doi:10.1016/s1471-4922(01)02205-x

**Gonin P and Trudel L** (2003) Detection and differentiation of *Entamoeba histolytica* and *Entamoeba dispar* isolates in clinical samples by PCR and enzyme-linked immunosorbent assay. *Journal of Clinical Microbiology* **41**, 237-241. doi:10.1128/JCM.41.1.237-241.2003

**Goncalves MLC, da Silva VL, de Andrade CM, Reinhard K, da Rocha GC, Le Bailly M, Bouchet F, Ferreira LF and Araujo A** (2004) Amoebiasis distribution in the past: first steps using an immunoassay technique. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **98**, 88-91. doi:10.1016/s0035-9203(03)00011-7

**Graff A, Bennion-Pedley E, Jones AK, Ledger ML, Deforce K, Degraeve A, Byl S and Mitchell PD** (2020) A comparative study of parasites in three latrines from Medieval and Renaissance Brussels, Belgium (14th–17th centuries). *Parasitology* **147**, 1443-1451. doi:10.1017/S0031182020001298

**Hasegawa M, Hashimoto T, Adachi J, Iwabe N and Miyata T** (1993) Early branchings in the evolution of eukaryotes: ancient divergence of *Entamoeba* that lacks mitochondria revealed by protein sequence data. *Journal of Molecular Evolution* **36**, 380-388. doi:10.1007/BF00182185

**Hénock Blaise NY and Dovie DBK** (2007) Diarrheal diseases in the history of public health. *Archives of Medical Research* **38**, 159-163. doi:10.1016/j.arcmed.2006.11.001

**Hlava J** (1887) O úplavici. Předbĕžné sdĕlení. *Časposis Lékařův Českých* **5**, 70-74.

**Hoare CA** (1950) Amoebiasis in Great Britain, with special reference to carriers. *British Medical Journal* **2**, 238-241. doi:10.1136/bmj.2.4673.238

**Hung C-C, Ji D-D, Sun H-Y, Lee Y-T, Hsu S-Y, Chang S-Y, Wu C-H, Chan Y-H, Hsiao C-F, Liu W-C and Colebunders R** (2008) Increased risk for *Entamoeba histolytica* infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. *PLoS Neglected Tropical Diseases* **2**, e175. doi:10.1371/journal.pntd.0000175

**Imperato PJ** (1981) A historical overview of amebiasis. *Bulletin of the New York Academy of Medicine* **57**, 175-187.

**Kartulis** (1886) Zur Aetiologie der Dysenterie in Aegypten. *Archive für pathologische Anatomie und Physiologie und für klinische Medicin* **105**, 521-531. doi:10.1007/BF01925504

**Knight R** (1980) The chemotherapy of amoebiasis. *Journal of Antimicrobial Chemotherapy* **6**, 577-593. doi:[10.1093/jac/6.5.577](https://doi.org/10.1093/jac/6.5.577)

**Koch R and Gaffky G** (1887) *Bericht über die Thätigkeit der zur Erforschung der Cholera im Jahre 1883 nach Egypten und Indien enstandten Kommission.* Berlin: Julius Springer.

**Kruse W and Pasquale A** (1894) Untersuchungen über Dysenterie und Leberabscess. [*Zeitschrift für Hygiene und Infektionskrankhei*](https://link.springer.com/journal/430)*ten* **16**, 1-148.

**Kuenen WA and Swellengrebel NH** (1913) Die Entamoeben des Menschen und ihre praktische Bedeutung. *Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. Abt. Originale, Medizinisch-hygienische, Bakteriologie, Virusforschung und Parasitologie* **71**, 378-410.

**Le Bailly M and Bouchet F** (2006) Paléoparasitologie et immunologie. L’exemple d’*Entamoeba histolytica*. *ArchéoSciences* **30**, 129-135. [doi:10.4000/archeosciences.281](https://doi.org/10.4000/archeosciences.281)

**Le Bailly M and Bouchet F** (2015) A first attempt to retrace the history of dysentery caused by *Entamoeba histolytica*. In Mitchell PD (ed), Sanitation, Latrines and Intestinal Parasites in Past Populations. Farnham, England: Ashgate Publishing Ltd, pp. 219-228.

**Le Bailly M, Romon T and Kacki S** (2014) New evidence of *Entamoeba histolytica* infections in pre-Columbian and colonial cemeteries in the Caribbean. *Journal of Parasitology* **100**, 684-686. doi:10.1645/13-476.1

**Le Bailly M, Maicher C and Dufour B** (2016) Archaeological occurrences and historical review of the human amoeba, *Entamoeba histolytica*, over the past 6000 years. *Infection, Genetics and Evolution* **42**, 34-40. doi:10.1016/j.meegid.2016.04.030

**Loftus B, Anderson I, Davies R, Alsmark UCM, Samuelson J, Amedeo P, Roncaglia P, Berriman M, Hirt RP, Mann BJ, Nozaki T, Suh B, Pop M, Duchene M, Ackers J, Tannich E, Leippe M, Hofer M, Bruchhaus I, Willhoeft U, Bhattacharya A, Chillingworth T, Churcher C, Hance Z, Harris B, Harris D, Jagels K, Moule S, Mungall K, Ormond D, Squares R, Whitehead S, Quail MA, Rabbinowitsch E, Norbertczak H, Price C, Wang Z, Guillén N, Gilchrist C, Stroup SE, Bhattacharya S, Lohia A, Foster PG, Sicheritz-Ponten T, Weber C, Singh U, Mukherjee C, El-Sayed NM, Petri WA Jr, Clark CG, Embley TM, Barrell B, Fraser CM and Hall N** (2005) The genome of the protist parasite *Entamoeba histolytica*. *Nature* **433**, 865-868. doi:10.1038/nature03291

**Lopez Elias F and Oliver-González J** (1959) Treatment of intestinal amebiasis with paromomycin (humatin). *Antibiotic Medicine and Clinical Therapy (New York, NY)* **6**, 584-585.

**Lösch F** (1875) Massenhafte Entwickelung von Amöben im Dickdarm. [*Archiv für pathologische Anatomie und Physiologie und für klinische Med*](https://link.springer.com/journal/428)*icin* **65**, 196-211. doi:10.1007/BF02028799

**Madeira F, Madhusoodanan N, Lee J, Eusebi A, Niewielska A, Tivey ARN, Lopez R and Butcher S** (2024) The EMBL-EBI Job Dispatcher sequence analysis tools framework in 2024. *Nucleic Acid Research* **52(W1)**, W521-525. doi:10.1093/nar/gkae241

**Mai Z, Ghosh S, Frisardi M, Rosenthal B, Rogers R and Samuelson J** (1999) Hsp60 is targeted to a cryptic mitochondrion‐derived organelle (“Crypton”) in the microaerophilic protozoan parasite *Entamoeba histolytica*. *Molecular and Cellular Biology*, **19**, 2198-2205. doi:10.1128/MCB.19.3.2198

**McAuley JB, Herwaldt BL, Stokes SL, Becher JA, Roberts JM, Michelson MK and Juranek DD** (1992) Diloxanide furoate for treating asymptomatic *Entamoeba histolytica* cyst passers: 14 years' experience in the United States. *Clinical Infectious Diseases* **15**, 464-468. doi:10.1093/clind/15.3.464

**Mitchell PD, Stern E and Tepper Y** (2008) Dysentery in the crusader kingdom of Jerusalem: an ELISA analysis of two medieval latrines in the City of Acre (Israel). *Journal of Archaeological Science* **35**, 1849-1853. [doi:10.1016/j.jas.2007.11.017](https://doi.org/10.1016/j.jas.2007.11.017)

**Nasrallah J, Akhoundi M, Haouchine D, Marteau A, Mantelet S, Wind P, Benamouzig R, Bouchaud O, Dhote R and Izri A** (2022) Updates on the worldwide burden of amoebiasis: A case series and literature review. *Journal of Infection and Public Health* **15**, 1134-1141. doi:10.1016/j.jiph.2022.08.013

**Osler W** (1890) On the *Amoeba coli* in dysentery and in dysenteric liver abscess. *Bulletin of the Johns Hopkins Hospital* **1**, 53-54.

**Parkes EA** (1846) *Remarks on the Dysentery and Hepatitis of India.* London: Longman, Brown, Green, and Longmans.

[**Petri WA Jr**](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Petri+WA+Jr&cauthor_id=1692809)**,** [**Jackson**](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Jackson+TF&cauthor_id=1692809) **FTHG,** [**Gathiram**](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Gathiram+V&cauthor_id=1692809) **V,** [**Kress**](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Kress+K&cauthor_id=1692809) **K,** [**Saffer**](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Saffer+LD&cauthor_id=1692809) **LD,** [**Snodgrass**](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Snodgrass+TL&cauthor_id=1692809) **TL,** [**Chapman**](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Chapman+MD&cauthor_id=1692809) **MD,** [**Keren**](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Keren+Z&cauthor_id=1692809) **Z,** [**Mirelman**](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Mirelman+D&cauthor_id=1692809) **D** (1990) Pathogenic and nonpathogenic strains of *Entamoeba histolytica* can be differentiated by monoclonal antibodies to the galactose-specific adherence lectin. *Infection and Immunity* **58**, 1802-1806. doi:10.1128/iai.58.6.1802-1806.1990

[**Powell**](https://www.cabidigitallibrary.org/authored-by/Powell/S+J) **SJ,** [**MacLeod**](https://www.cabidigitallibrary.org/authored-by/Macleod/I) **I,** [**Wilmot**](https://www.cabidigitallibrary.org/authored-by/Wilmot/A+J) **AJ,** [**Elsdon-Dew**](https://www.cabidigitallibrary.org/authored-by/Elsdon-dew/R) **R** (1966) Metronidazole in amoebic dysentery and amoebic liver abscess. *Lancet* **288**, 1329-1331. doi:10.1016/s0140-6736(66)92081-2

**Quincke JI and Roos E** (1893) *Ueber Amöben-Enteritis*. Berliner Klinische Wochenschrift **30**, 1089-1094.

**Rogers L** (1910) The prevention and treatment of amoebic abscess of the liver. *Philippine Journal of Science* **5B**, 219-228.

**Rogers L** (1912) The rapid cure of amoebic dysentery and hepatitis by hypodermic injections of soluble salts of emetine. *British Medical Journal* **1**, 1424-1425. doi:10.1136/bmj.1.2686.1424

**Roy SW, Irimia M and Penny D** (2006) Very little intron gain in *Entamoeba histolytica* genes laterally transferred from prokaryotes. *Molecular Biology and Evolution* **23**, 1824-1827. doi:10.1093/molbev/msl061

**Royer TL, Gilchrist C, Kabir M, Arju T, Ralston KS, Haque R, Clark CG and Petri WA Jr** (2012) *Entamoeba bangladeshi* nov. sp., Bangladesh. *Emerging Infectious Diseases* **18**, 1543-1545. doi:10.3201/eid1809.120122

**Sanie A, ElBakri A and AbuOdeh R** (2012) Amoebiasis in the tropics: epidemiology and pathogenesis. In Rodriguez-Morales AJ (ed). Current Topics in Tropical Medicine. Rijeka, Croatia: InTech, pp. 201-226. doi:10.5772/26810

**Sargeaunt PG, Williams JE and Grene JD** (1978) The differentiation of invasive and non-invasive *Entamoeba histolytica* by isoenzyme electrophoresis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **72**, 519-521. doi:10.1016/0035-9203(78)90174-8

**Schaudinn F** (1903) Untersuchungen über die Fortpflanzung einiger Rhizopoden. (Vorläufige Mittheilung). *Arbeiten der Kaiserlichen Gesundheitsamte* **19**: 547-576.

**Shirley D-AT, Farr L, Watanabe K and Moonah S** (2018) A review of the global burden, new diagnostics, and current therapeutics for amebiasis. *Open Forum Infectious Diseases* **5**, ofy161. doi:10.1093/ofid/ofy161

**Silberman JD, Clark CG, Diamond LS and Sogin ML** (1999) Phylogeny of the genera *Entamoeba* and *Endolimax* as deduced from small-subunit ribosomal RNA sequences. *Molecular Biology and Evolution* **16**, 1740-1751. doi:10.1093/oxfordjournals.molbev.a026086

**Simić T** (1931a) Présence de I’*Entamoeba dispar* Brumpt dans le sud de la Yougoslavie (Macédoine Serbe). *Annales de Parasitologie Humaine et Comparée* **9**, 289-302.

**Simić T** (1931b) Infection expérimentale de I’homme par *Entamoeba dispar* Brumpt. *Annales de Parasitologie Humaine et Comparée* **9**, 385-391.

**Simić T** (1931c) Étude expérimentale complémentaire de 1’*Entamoeba dispar* Brumpt, de Skoplje, sur le chat. *Annales de Parasitologie Humaine et Comparée* **9**, 497-502.

**Simon SK** (1909) Amebic dysentery. *Journal of the American Medical Association* **53**, 1526-1532. doi:10.1001/jama.1909.92550190001001a

**Sogin ML** (1991) Early evolution and the origin of eukaryotes. *Current Opinion in Genetics and Development* **1**, 457-463. doi:10.1016/s0959-437x(05)80192-3

**Stensvold CR, Lebbad M and Clark CG** (2010) Genetic characterisation of uninucleated cyst-producing *Entamoeba* spp. from ruminants. *International Journal for Parasitology* **40**, 775-778. doi:10.1016/j.ijpara.2010.03.003

**Steverding, D** (2020) The spreading of parasites by human migratory activities, *Virulence* **11**, 1177-1191. doi:10.1080/21505594.2020.1809963

**Swaminathan A, Torresi J, Schlagenhauf P, Thursky K, Wilder-Smith A, Connor BA, Schwartz E, von Sonnenberg F, Keystone J, O’Brien DP and for the GeoSentinel Network** (2009) A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. *Journal of Infection* **59**, 19-27. doi:10.1016/j.jinf.2009.05.008

**Tachibana H, Yanagi T, Pandey K, Cheng X-J, Kobayashi S, Sherchand JB and Kanbara H** (2007) An *Entamoeba* sp. strain isolated from rhesus monkey is virulent but genetically different from *Entamoeba histolytica*. *Molecular and Biochemical Parasitology* **153**, 107-114. doi:10.1016/j.molbiopara.2007.02.006

[**Tannich**](https://pubmed.ncbi.nlm.nih.gov/?term=%22Tannich%20E%22%5BAuthor%5D) **E,** [**Horstmann**](https://pubmed.ncbi.nlm.nih.gov/?term=%22Horstmann%20RD%22%5BAuthor%5D) **RD,** [**Knobloch**](https://pubmed.ncbi.nlm.nih.gov/?term=%22Knobloch%20J%22%5BAuthor%5D) **J,** [**Arnold**](https://pubmed.ncbi.nlm.nih.gov/?term=%22Arnold%20HH%22%5BAuthor%5D) **HH** (1989) Genomic DNA differences between pathogenic and nonpathogenic *Entamoeba histolytica*. *Proceedings of the National Academy of Sciences of the United States of America* **86**, 5118-5122. doi:10.1073/pnas.86.13.5118

**Teixeira JE and Huston CD** (2008) Evidence of a continuous endoplasmic reticulum in the protozoan parasite *Entamoeba histolytica*. *Eukaryotic Cell* **7**, 1222-1226. doi:10.1128/EC.00007-08.

**Tovar J, Fischer A and Clark CG** (1999) The mitosome, a novel organelle related to mitochondria in the amitochondrial parasite *Entamoeba histolytica*. *Molecular Microbiology*, **32**, 1013-1021. doi:10.1046/j.1365-2958.1999.01414.x

**Twining W** (1832) *Clinical Illustrations of the More Important Diseases of Bengal, with the Result of an Inquiry into their Pathology and Treatment.* London: Padbury, Allen and Co.; Calcutta: W. Thacker and Co.

**Uribe-Querol E and Rosales C** (2020) Immune response to the enteric parasite *Entamoeba histolytica*. *Physiology (Bethesda)* **35**, 244-260. doi:10.1152/physiol.00038.2019

**van der Giezen M, León‐Avila G and Tovar J** (2005) Characterization of chaperonin 10 (Cpn10) from the intestinal human pathogen *Entamoeba histolytica*. *Microbiology*, **151**, 3107-3115. doi:10.1099/mic.0.28068-0

**Vedder EB** (1912) An experimental study of the action of ipecacuanha on amoebae. *Far Eastern Association of Tropical Medicine: Abstract of the Transaction of the Second Biannual Congress held in Hong Kong* **1912**, 87-81.

**Walker EL and Sellards AW** (1913) Experimental entamoebic dysentery. *The Philippine Journal of Science Section B Tropical Medicine* **7**, 253-331.

**Watanabe K, Gatanaga H, Escueta-de Cadiz A, Tanuma J, Nozaki T and Oka S** (2011) Amebiasis in HIV-1-infected Japanese men: clinical features and response to therapy. *PLoS Neglected Tropical Diseases* **5**, e1318. doi:10.1371/journal.pntd.0001318

**Weedall GD and Hall N** (2011) Evolutionary genomics of *Entamoeba*. *Research in Microbiology* **162**, 637-645. doi:10.1016/j.resmic.2011.01.007

**WHO** (1997) Amoebiasis. *Weekly Epidemiological Record* **72**, 97-99.

**Witenberg G** (1961) Human parasites in archaeological findings. *Bulletin of the Israel Exploration Society* **25**, 86.

**Yeh H-Y, Pluskowski A, Kalējs U and Mitchell PD** (2014) Intestinal parasites in a mid-14th century latrine from Riga, Latvia: fish tapeworm and the consumption of uncooked fish in the medieval eastern Baltic region. *Journal of Archaeological Science* **49**, 83–89. doi:10.1016/j.jas.2014.05.001

**Yeh H-Y, Prag K, Clamer C, Humbert J-B, and Mitchell PD** (2015) Human intestinal parasites from a Mamluk period cesspool in the Christian quarter of Jerusalem: potential indicators of long distance travel in the 15th century AD. *International Journal of Paleopathology* **9**, 69-75. doi:10.1016/j.ijpp.2015.02.003

**Zulfiqar H, Mathew G and Horrall S** (2023) Amebiasis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.



**Figure 1.** Phylogenetic relationship among Entamoeba species based on small-subunit ribosomal RNA sequences. The phylogenetic tree was calculated using the neighbour-joining method with the programme Clustal Omega (Madeira et al., 2024). Species producing cysts with 8 nuclei are highlighted in green, those producing cysts with 4 nuclei in blue, and those producing cysts with 1 nucleus in red. Species producing no cysts are shown in black.



**Figure 2.** Drawings of amoebas found in the stool of an amoebic dysentery patient investigated by Lösch (Lösch, 1875). **a**, stationary amoeba; **b-h**, moving amoebas. **a** and **g**, neither nucleus nor vacuoles are visible; **c**, **e**, **f**, and **h**, nucleus and vacuoles are visible; **b** and **d**, only vacuoles are visible. **b**, **d**, **e**, and **h**, with one pseudopod; **c** and **g**, with two pseudopods. Magnification, 500X. No permission is needed for reusing Lösch’s drawings as their copyright has expired.



**Figure 3.** Portrait of Fritz Schaudinn, who proposed the name *Entamoeba histolytica* for the etiological agent of amoebic dysentery. Wikimedia Commons, Link: https://upload.wikimedia.org/wikipedia/commons/4/44/Fritz\_Richard\_Schaudinn.png. Tragically, Schaudinn died in 1906, aged 34, while travellling back to Germany from an International Medicine Meeting in Lisbon, Portugal. He fell suddenly ill with gastrointestinal amoebic abscesses and had to undergo emergency surgery onboard the ship, and eventually died of septicaemia. The amoebic infection was probably self-inflicted (Imperato, 1981).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Paronomycin | | | | |
| Diiodohydroxyquinoline | | | Diloxamide furoate | |
|  | R:    Metronidazole | R:    Tinidazole | | R:    Ornidazole |
| Nitazoxamide | | | | |

**Figure 4.** Chemical structure of currently licensed drugs for the treatment of *E. histolytica* infections.